Pharmagipfel

Dialog between Politics and the Pharmaceutical Industry


The Bavarian Pharmagipfel aims to create with its partners a sustainable and financially viable healthcare system that promotes progress and patient orientation in medicine and enables access to innovative diagnostics and therapy, including digital innovations, for all patients.

To this end, Bavaria has already provided decisive impetus in recent years for measures at the federal level to ensure the supply of medicines.

On November 9, as part of the next phase of the Pharmagipfel, Bavaria's Minister of Health Klaus Holetschek and State Secretary of Economic Affairs Roland Weigert signed a corresponding paper in Martinsried/Munich - - to strengthen Bavaria as a location for pharmaceuticals and to improve the framework conditions for a safe supply of pharmaceuticals.

The declaration provides a large number of very concrete measures, including the strengthening of patent protection and simplification of administrative processes, as well as an opt-out model for the use of data from the electronic patient record (ePA) for research purposes.

The measures in the now updated Joint Declaration of the Bavarian Pharmagipfel (German only) are to be implemented at the federal level. Signatories on the part of the pharmaceutical associations are the Bundesverband der Arzneimittelhersteller e.V. (B.A.H), the Biotechnology Industry Organization Germany e.V. (BIO Deutschland), the Bavarian regional association of the German Pharmaceutical Industry Association. (BPI), Pro Generika e.V. and the Association of Research-Based Pharmaceutical Companies e.V. (vfa).

Specifically, the politicians and pharmaceutical associations advocate the following measures:

  • Strengthening patent protection
  • Simplification of administrative processes
  • Use of health data for research & development
  • Improving framework conditions for advanced therapies
  • Joining forces in the fight against cancer

Under the moderation of BioM, the exchange between the units involved in clinical research in companies and (university) hospitals is to be supported in further workshops within the framework of a new edition of the "Clinical Research" round table. The aim here is to identify and realize further improvement measures.

In addition, synergy potentials regarding the strengthening of the hospital IT infrastructure within the medical informatics initiative of the Federal Ministry of Education and Research and other suitable projects and organizations are to be evaluated.

To this end, a Clinical Research Working Group including BioM, the State Ministry of Health and Care, the State Ministry of Economics, Regional Development and Energy, and representatives of the pharmaceutical industry is to meet to discuss legal and sub-legal measures, including structural measures to improve infrastructure and incentives.

Photo: The partners of the "Bavarian Pharmagipfel" signing the joint declaration. © StMWi/E. Neureuther.

Prof. Dr. Horst Domdey
Prof. Dr. Horst Domdey

Managing Director


Joint Declaration of the "Bavarian Pharmagipfel conference" of November 9, 2021 (pdf)